• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Novo Nordisk increases commitment to cell therapies

biospectrumasiaMay 17, 2018

Tag: Novo Nordisk , cell , BioLamina

BioLamina and collaborators have partnered with Novo Nordisk, a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced by BioLamina.

Novo Nordisk is increasing its commitment to cell therapies, including areas outside of diabetes. The three cell therapy projects they have licensed are all based on BioLamina technology. These projects aim to treat Parkinson's disease, heart failure and loss of vision, all severe chronic conditions.

Malin Parmar's research group at Lund University and Karl Tryggvason's research group at Duke-NUS in Singapore have developed potential cell therapies based on BioLamina's unique Biolaminin matrices. Both groups have signed research and potential licensing agreements with Novo Nordisk with the aim to develop these projects further together with Novo Nordisk, enabling a translation of cell therapy pre-clinical studies, to clinical trials and eventually towards patient treatments.

Register as Visitor to CPhI China 2018!

Previous:Japan approves stem cell based trials for heart treatment

Next:US, China to sign MoU for Biotechnology Innovation Centre

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Novo Nordisk increases commitment to cell therapies | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

SF003 Serum-free Media for MDCK Cells

SF003 Serum-free Media for MDCK Cells
Low-substituted Hydroxypropyl Cellulose

Low-substituted Hydroxypropyl Cellulose
 Cell Therapy Isolator

 Cell Therapy Isolator
Celer Series Serum-free Media for 293 Cells

Celer Series Serum-free Media for 293 Cells
Cell Bottle

Cell Bottle
High Purity Cellulose Depth filter pads

High Purity Cellulose Depth filter pads
Ethyl Cellulose

Ethyl Cellulose

Fast delivery CMC/Sodium carboxymethyl cellulose cas 9004-32-4/Food Grade/Daily Cleaning

Fast delivery CMC/Sodium carboxymethyl cellulose cas 9004-32-4/Food Grade/Daily Cleaning
XT-180 Type Adjustable Cellophane 3D Overwrapping Machine(With Tear Tape)

XT-180 Type Adjustable Cellophane 3D Overwrapping Machine(With Tear Tape)
High-pressure cell shatter/High pressure homogenizer/HPH-P SERIES HIGH PRESSURE HOMOGENIZER

High-pressure cell shatter/High pressure homogenizer/HPH-P SERIES HIGH PRESSURE HOMOGENIZER

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service